ALEMBICLTDAlembic Limited
Realty · Real Estate - Development · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Alembic Limited engages in real estate business in India and internationally. It operates through Active Pharmaceutical Ingredient (API) and Real Estate segments. The company constructs residential and commercial real estate projects; provides project management and marketing consultancy services; and leases commercial properties. It also manufactures and markets fermentation and chemistry based active pharmaceutical ingredient; and engages in research and development activities. In addition, it is involved in power generation through co-generation plants and wind power sources. The company serves individuals, entrepreneurs, corporates, business houses, HNIs, NRIs, and pharmaceutical companies. The company was incorporated in 1907 and is based in Vadodara, India. Alembic Limited is a subsidiary of Nirayu Pvt. Ltd.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Debt/Equity: 0.00
- • Promoter holding: 72.2%
- • Valuation vs sector: P/E 8.5 vs sector 24.5
- • RSI: 59
- • MACD: bullish
- • Price vs EMA21: above
- • Golden Cross signal (setup quality 75%)
Bull case
- • Debt/Equity: 0.00
- • Promoter holding: 72.2%
- • Valuation vs sector: P/E 8.5 vs sector 24.5
- • RSI: 59
Bear case
- • Revenue growth: -0.4% YoY
- • Profit growth: -2.3% YoY
- • Volume: 0.2x 20-day average
- • Sector momentum: sector -1.8% (1m)
Key risks
- • Revenue growth: -0.4% YoY
- • Profit growth: -2.3% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹4.44). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.